Skip to main content
Top
Published in: BMC Primary Care 1/2016

Open Access 01-12-2016 | Debate

Communicating statin evidence to support shared decision-making

Authors: Bruce Barrett, Jason Ricco, Margaret Wallace, David Kiefer, Dave Rakel

Published in: BMC Primary Care | Issue 1/2016

Login to get access

Abstract

Background

The practice of clinical medicine rests on a foundation of ethical principles as well as scientific knowledge. Clinicians must artfully balance the principle of beneficence, doing what is best for patients, with autonomy, allowing patients to make their own well-informed health care decisions. The clinical communication process is complicated by varying degrees of confidence in scientific evidence regarding patient-oriented benefits, and by the fact that most medical options are associated with possible harms as well as potential benefits.

Discussion

Evidence-based clinical guidelines often neglect patient-oriented issues involved with the thoughtful practice of shared decision-making, where individual values, goals, and preferences should be prioritized. Guidelines on the use of statin medications for preventing cardiovascular events are a case in point. Current guidelines endorse the use of statins for people whose 10-year risk of cardiovascular events is as low as 7.5 %. Previous guidelines set the 10-year risk benchmark at 20 %. Meta-analysis of randomized trials suggests that statins can reduce cardiovascular event rates by about 25 %, bringing 10-year risk from 7.5 to 5.6 %, for example, or from 20 to 15 %. Whether or not these benefits should justify the use of statins for individual patients depends on how those advantages are valued in comparison with disadvantages, such as side effect risks, and with inconveniences associated with taking a pill each day and visiting clinicians and laboratories regularly.

Conclusions

Whether or not the overall benefit-harm balance justifies the use of a medication for an individual patient cannot be determined by a guidelines committee, a health care system, or even the attending physician. Instead, it is the individual patient who has a fundamental right to decide whether or not taking a drug is worthwhile. Researchers and professional organizations should endeavor to develop shared decision-making tools that provide up-to-date best evidence in easily understandable formats, so as to assist clinicians in helping their patients to make the decisions that are right for them.
Literature
1.
go back to reference Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–292.CrossRefPubMed Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–292.CrossRefPubMed
2.
go back to reference National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE guidelines [CG181] 2014. https://www.nice.org.uk/guidance/cg181. Accessed 31 March 2016. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE guidelines [CG181] 2014. https://​www.​nice.​org.​uk/​guidance/​cg181. Accessed 31 March 2016.
3.
go back to reference Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.CrossRefPubMedPubMedCentral Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.CrossRefPubMedPubMedCentral
4.
go back to reference James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.CrossRefPubMed James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.CrossRefPubMed
5.
go back to reference Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010;122:847–9.CrossRefPubMed Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010;122:847–9.CrossRefPubMed
6.
go back to reference Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev. 2012;8:CD006742.PubMed Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev. 2012;8:CD006742.PubMed
7.
go back to reference Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288–98.CrossRefPubMed Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288–98.CrossRefPubMed
8.
go back to reference Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358:2630–3.CrossRefPubMed Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358:2630–3.CrossRefPubMed
9.
go back to reference Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey SG, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.PubMed Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey SG, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.PubMed
10.
go back to reference Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.CrossRefPubMed Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.CrossRefPubMed
11.
go back to reference Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170:1024–31.CrossRefPubMed Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170:1024–31.CrossRefPubMed
12.
go back to reference Montori VM, Brito JP, Ting HH. Patient-centered and practical application of new high cholesterol guidelines to prevent cardiovascular disease. JAMA. 2014;311:465–6.CrossRefPubMed Montori VM, Brito JP, Ting HH. Patient-centered and practical application of new high cholesterol guidelines to prevent cardiovascular disease. JAMA. 2014;311:465–6.CrossRefPubMed
13.
go back to reference Krumholz HM. The new cholesterol and blood pressure guidelines: perspective on the path forward. JAMA. 2014;311:1403–5.CrossRefPubMed Krumholz HM. The new cholesterol and blood pressure guidelines: perspective on the path forward. JAMA. 2014;311:1403–5.CrossRefPubMed
14.
go back to reference D’Agostino Sr RB, Ansell BJ, Mora S, Krumholz HM. Clinical decisions. The guidelines battle on starting statins. N Engl J Med. 2014;370:1652–8.CrossRefPubMed D’Agostino Sr RB, Ansell BJ, Mora S, Krumholz HM. Clinical decisions. The guidelines battle on starting statins. N Engl J Med. 2014;370:1652–8.CrossRefPubMed
15.
go back to reference Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;129:S1–45.CrossRefPubMed Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;129:S1–45.CrossRefPubMed
16.
go back to reference Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57:1404–23.CrossRefPubMedPubMedCentral Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57:1404–23.CrossRefPubMedPubMedCentral
17.
go back to reference National Institute for Health and Care Excellence. Statins for the prevention of cardiovascular events. Technology appraisal 94. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance [TA94]. 2006. https://www.nice.org.uk/guidance/ta94. Accessed 31 March 2016. National Institute for Health and Care Excellence. Statins for the prevention of cardiovascular events. Technology appraisal 94. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance [TA94]. 2006. https://​www.​nice.​org.​uk/​guidance/​ta94. Accessed 31 March 2016.
19.
go back to reference Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7:e29849.CrossRefPubMed Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7:e29849.CrossRefPubMed
20.
go back to reference Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.CrossRefPubMed Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.CrossRefPubMed
22.
go back to reference Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769–81.CrossRefPubMed Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769–81.CrossRefPubMed
23.
24.
go back to reference Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104:109–24.CrossRefPubMed Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104:109–24.CrossRefPubMed
25.
go back to reference Ioannidis JP. More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines. JAMA. 2014;311:463–4.CrossRefPubMed Ioannidis JP. More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines. JAMA. 2014;311:463–4.CrossRefPubMed
26.
go back to reference Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78:393–403.CrossRefPubMed Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78:393–403.CrossRefPubMed
27.
28.
go back to reference Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol. 2006;97:32C–43.CrossRefPubMed Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol. 2006;97:32C–43.CrossRefPubMed
29.
go back to reference Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med. 2014;12:51.CrossRefPubMedPubMedCentral Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med. 2014;12:51.CrossRefPubMedPubMedCentral
30.
go back to reference Mansi IA, Mortensen EM, Pugh MJ, Wegner M, Frei CR. Incidence of musculoskeletal and neoplastic diseases in patients on statin therapy: results of a retrospective cohort analysis. Am J Med Sci. 2013;345:343–8.CrossRefPubMed Mansi IA, Mortensen EM, Pugh MJ, Wegner M, Frei CR. Incidence of musculoskeletal and neoplastic diseases in patients on statin therapy: results of a retrospective cohort analysis. Am J Med Sci. 2013;345:343–8.CrossRefPubMed
31.
go back to reference Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526–34.CrossRefPubMedPubMedCentral Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526–34.CrossRefPubMedPubMedCentral
32.
33.
go back to reference Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012;172:1180–2.PubMedPubMedCentral Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012;172:1180–2.PubMedPubMedCentral
34.
go back to reference Mikus CR, Boyle LJ, Borengasser SJ, Oberlin DJ, Naples SP, Fletcher J, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol. 2013;62:709–14.CrossRefPubMedPubMedCentral Mikus CR, Boyle LJ, Borengasser SJ, Oberlin DJ, Naples SP, Fletcher J, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol. 2013;62:709–14.CrossRefPubMedPubMedCentral
35.
go back to reference Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.CrossRefPubMed Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.CrossRefPubMed
36.
go back to reference Ma Y, Culver A, Rossouw J, Olendzki B, Merriam P, Lian B, et al. Statin therapy and the risk for diabetes among adult women: do the benefits outweigh the risk? Ther Adv Cardiovasc Dis. 2013;7:41–4.CrossRefPubMed Ma Y, Culver A, Rossouw J, Olendzki B, Merriam P, Lian B, et al. Statin therapy and the risk for diabetes among adult women: do the benefits outweigh the risk? Ther Adv Cardiovasc Dis. 2013;7:41–4.CrossRefPubMed
37.
go back to reference Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121:1069–77.CrossRefPubMedPubMedCentral Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121:1069–77.CrossRefPubMedPubMedCentral
38.
go back to reference Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med. 2012;172:144–52.CrossRefPubMed Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med. 2012;172:144–52.CrossRefPubMed
39.
go back to reference Robinson JG. Statins and diabetes risk: how real is it and what are the mechanisms? Curr Opin Lipidol. 2015;26:228–35.CrossRefPubMed Robinson JG. Statins and diabetes risk: how real is it and what are the mechanisms? Curr Opin Lipidol. 2015;26:228–35.CrossRefPubMed
40.
go back to reference Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.CrossRefPubMedPubMedCentral Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.CrossRefPubMedPubMedCentral
41.
go back to reference Golomb BA, Evans MA. Re: Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2008;70:2349–50.CrossRefPubMed Golomb BA, Evans MA. Re: Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2008;70:2349–50.CrossRefPubMed
42.
go back to reference Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf. 2007;30:195–201.CrossRefPubMed Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf. 2007;30:195–201.CrossRefPubMed
43.
go back to reference Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM. 2004;97:229–35.CrossRefPubMed Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM. 2004;97:229–35.CrossRefPubMed
44.
go back to reference Golomb BA, Evans MA. Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease. Med J Aust. 2007;187:253.PubMed Golomb BA, Evans MA. Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease. Med J Aust. 2007;187:253.PubMed
45.
go back to reference Golomb BA, Evans MA. Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8:373–418.CrossRefPubMedPubMedCentral Golomb BA, Evans MA. Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8:373–418.CrossRefPubMedPubMedCentral
46.
go back to reference Chaipichit N, Krska J, Pratipanawatr T, Jarernsiripornkul N. Statin adverse effects: patients’ experiences and laboratory monitoring of muscle and liver injuries. Int J Clin Pharm. 2015;37:355–64.CrossRefPubMed Chaipichit N, Krska J, Pratipanawatr T, Jarernsiripornkul N. Statin adverse effects: patients’ experiences and laboratory monitoring of muscle and liver injuries. Int J Clin Pharm. 2015;37:355–64.CrossRefPubMed
47.
go back to reference Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med. 2015;30:348–58.CrossRefPubMedPubMedCentral Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med. 2015;30:348–58.CrossRefPubMedPubMedCentral
48.
go back to reference Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012–22.CrossRefPubMedPubMedCentral Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012–22.CrossRefPubMedPubMedCentral
49.
go back to reference Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347:f6123.CrossRefPubMed Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347:f6123.CrossRefPubMed
50.
51.
go back to reference Montori VM, Brito JP, Murad MH. The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. JAMA. 2013;310:2503–4.CrossRefPubMed Montori VM, Brito JP, Murad MH. The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. JAMA. 2013;310:2503–4.CrossRefPubMed
52.
53.
go back to reference Elwyn G, Edwards A, Hood K, Robling M, Atwell C, Russell I, et al. Achieving involvement: process outcomes from a cluster randomized trial of shared decision making skill development and use of risk communication aids in general practice. Fam Pract. 2004;21:337–46.CrossRefPubMed Elwyn G, Edwards A, Hood K, Robling M, Atwell C, Russell I, et al. Achieving involvement: process outcomes from a cluster randomized trial of shared decision making skill development and use of risk communication aids in general practice. Fam Pract. 2004;21:337–46.CrossRefPubMed
54.
go back to reference Sandman L, Munthe C. Shared decision-making and patient autonomy. Theor Med Bioeth. 2009;30:289–310.CrossRefPubMed Sandman L, Munthe C. Shared decision-making and patient autonomy. Theor Med Bioeth. 2009;30:289–310.CrossRefPubMed
55.
go back to reference Sieber WJ, Kaplan RM. Informed adherence: The need for shared medical decision making. Control Clin Trials. 2000;21:233s–40.CrossRefPubMed Sieber WJ, Kaplan RM. Informed adherence: The need for shared medical decision making. Control Clin Trials. 2000;21:233s–40.CrossRefPubMed
56.
go back to reference Baird M, Blount A, Brungardt S, Dickinson P, Dietrich A, Epperly T, et al. Joint principles: integrating behavioral health care into the patient-centered medical home. Ann Fam Med. 2014;12:183–5.CrossRef Baird M, Blount A, Brungardt S, Dickinson P, Dietrich A, Epperly T, et al. Joint principles: integrating behavioral health care into the patient-centered medical home. Ann Fam Med. 2014;12:183–5.CrossRef
57.
58.
go back to reference Geyman JP. POEMs as a paradigm shift in teaching, learning, and clinical practice. Patient-oriented evidence that matters. J Fam Pract. 1999;48:343–4.PubMed Geyman JP. POEMs as a paradigm shift in teaching, learning, and clinical practice. Patient-oriented evidence that matters. J Fam Pract. 1999;48:343–4.PubMed
60.
go back to reference Shaughnessy AF, Slawson DC. POEMs: patient-oriented evidence that matters. Ann Intern Med. 1997;126:667.CrossRefPubMed Shaughnessy AF, Slawson DC. POEMs: patient-oriented evidence that matters. Ann Intern Med. 1997;126:667.CrossRefPubMed
61.
go back to reference Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA. 2012;307:1583–4.CrossRefPubMed Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA. 2012;307:1583–4.CrossRefPubMed
63.
go back to reference Department of Health NHS. Equity and excellence: Liberating the NHS. London: The Stationary Office; 2010. Department of Health NHS. Equity and excellence: Liberating the NHS. London: The Stationary Office; 2010.
64.
go back to reference Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;1:CD001431.PubMed Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;1:CD001431.PubMed
67.
go back to reference Diener A, Celemin-Heinrich S, Wegscheider K, Kolpatzik K, Tomaschko K, Altiner A, et al. In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study. BMC Fam Pract. 2013;14:13. http://www.arriba-hausarzt.de/.CrossRefPubMedPubMedCentral Diener A, Celemin-Heinrich S, Wegscheider K, Kolpatzik K, Tomaschko K, Altiner A, et al. In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study. BMC Fam Pract. 2013;14:13. http://​www.​arriba-hausarzt.​de/​.​CrossRefPubMedPubMedCentral
68.
go back to reference Hirsch O, Keller H, Krones T, Donner-Banzhoff N. Acceptance of shared decision making with reference to an electronic library of decision aids (arriba-lib) and its association to decision making in patients: an evaluation study. Implement Sci. 2011;6:70.CrossRefPubMedPubMedCentral Hirsch O, Keller H, Krones T, Donner-Banzhoff N. Acceptance of shared decision making with reference to an electronic library of decision aids (arriba-lib) and its association to decision making in patients: an evaluation study. Implement Sci. 2011;6:70.CrossRefPubMedPubMedCentral
69.
go back to reference Nelson W, Reyna V. Numeracy: A critical (and often overlooked) competence for health decision making. Ann Behav Med. 2007;33:S8. Nelson W, Reyna V. Numeracy: A critical (and often overlooked) competence for health decision making. Ann Behav Med. 2007;33:S8.
70.
go back to reference Peters E, Vastfjall D, Slovic P, Mertz CK, Mazzocco K, Dickert S. Numeracy and decision making. Psychol Sci. 2006;17:407–13.CrossRefPubMed Peters E, Vastfjall D, Slovic P, Mertz CK, Mazzocco K, Dickert S. Numeracy and decision making. Psychol Sci. 2006;17:407–13.CrossRefPubMed
71.
go back to reference Andrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66:726–35.CrossRefPubMed Andrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66:726–35.CrossRefPubMed
72.
go back to reference Ades PA. A controversial step forward: a commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Coron Artery Dis. 2014;25:360–3.CrossRefPubMedPubMedCentral Ades PA. A controversial step forward: a commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Coron Artery Dis. 2014;25:360–3.CrossRefPubMedPubMedCentral
73.
go back to reference Wallace ML, Ricco JA, Barrett B: Screening strategies for cardiovascular disease in aymptomatic adults. Primary Care: Clinics in Office Practice 2014, In press. Wallace ML, Ricco JA, Barrett B: Screening strategies for cardiovascular disease in aymptomatic adults. Primary Care: Clinics in Office Practice 2014, In press.
74.
go back to reference Koschack J, Weibezahl L, Friede T, Himmel W, Makedonski P, Grabowski J. Scientific versus experiential evidence: Discourse analysis of the chronic cerebrospinal venous insufficiency debate in a multiple sclerosis forum. J Med Internet Res. 2015;17:e159.CrossRefPubMedPubMedCentral Koschack J, Weibezahl L, Friede T, Himmel W, Makedonski P, Grabowski J. Scientific versus experiential evidence: Discourse analysis of the chronic cerebrospinal venous insufficiency debate in a multiple sclerosis forum. J Med Internet Res. 2015;17:e159.CrossRefPubMedPubMedCentral
75.
go back to reference Ziebland S, Herxheimer A. How patients’ experiences contribute to decision making: illustrations from DIPEx (personal experiences of health and illness). J Nurs Manag. 2008;16:433–9.CrossRefPubMed Ziebland S, Herxheimer A. How patients’ experiences contribute to decision making: illustrations from DIPEx (personal experiences of health and illness). J Nurs Manag. 2008;16:433–9.CrossRefPubMed
76.
go back to reference Jaeschke R, Singer J, Guyatt GH. Measurement of health status: Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407–15.CrossRefPubMed Jaeschke R, Singer J, Guyatt GH. Measurement of health status: Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407–15.CrossRefPubMed
77.
go back to reference Barrett B, Brown R, Mundt M, Dye L, Alt J, Safdar N, et al. Using benefit harm tradeoffs to estimate sufficiently important difference: the case of the common cold. Med Decis Mak. 2005;25:47–55.CrossRef Barrett B, Brown R, Mundt M, Dye L, Alt J, Safdar N, et al. Using benefit harm tradeoffs to estimate sufficiently important difference: the case of the common cold. Med Decis Mak. 2005;25:47–55.CrossRef
78.
go back to reference Barrett B, Brown D, Mundt M, Brown R. Sufficiently important difference: expanding the framework of clinical significance. Med Decis Mak. 2005;25:250–61.CrossRef Barrett B, Brown D, Mundt M, Brown R. Sufficiently important difference: expanding the framework of clinical significance. Med Decis Mak. 2005;25:250–61.CrossRef
79.
go back to reference Barrett B, Brown R, Mundt M. Comparison of anchor-based and distributional approaches in estimating important difference in common cold. Qual Life Res. 2008;17:75–85.CrossRefPubMed Barrett B, Brown R, Mundt M. Comparison of anchor-based and distributional approaches in estimating important difference in common cold. Qual Life Res. 2008;17:75–85.CrossRefPubMed
80.
go back to reference Barrett B. Sufficiently important difference: Concepts, caveats, and challenges. Med Decis Mak. 2013;33:869–74.CrossRef Barrett B. Sufficiently important difference: Concepts, caveats, and challenges. Med Decis Mak. 2013;33:869–74.CrossRef
81.
go back to reference Ferreira ML, Herbert RD, Ferreira PH, Latimer J, Ostelo RW, Nascimento DP, et al. A critical review of methods used to determine the smallest worthwhile effect of interventions for low back pain. J Clin Epidemiol. 2012;65:253–61.CrossRefPubMed Ferreira ML, Herbert RD, Ferreira PH, Latimer J, Ostelo RW, Nascimento DP, et al. A critical review of methods used to determine the smallest worthwhile effect of interventions for low back pain. J Clin Epidemiol. 2012;65:253–61.CrossRefPubMed
82.
go back to reference Franco MR, Ferreira ML, Howard K, Sherrington C, Rose J, Haines TP, Ferreira P. How big does the effect of an intervention have to be? Application of two novel methods to determine the smallest worthwhile effect of a fall prevention programme: a study protocol. BMJ Open. 2013;3(2):1–5. http://bmjopen.bmj.com/content/3/2/e002355.full. Accessed 31 March 2016. Franco MR, Ferreira ML, Howard K, Sherrington C, Rose J, Haines TP, Ferreira P. How big does the effect of an intervention have to be? Application of two novel methods to determine the smallest worthwhile effect of a fall prevention programme: a study protocol. BMJ Open. 2013;3(2):1–5. http://​bmjopen.​bmj.​com/​content/​3/​2/​e002355.​full. Accessed 31 March 2016.
Metadata
Title
Communicating statin evidence to support shared decision-making
Authors
Bruce Barrett
Jason Ricco
Margaret Wallace
David Kiefer
Dave Rakel
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Primary Care / Issue 1/2016
Electronic ISSN: 2731-4553
DOI
https://doi.org/10.1186/s12875-016-0436-9

Other articles of this Issue 1/2016

BMC Primary Care 1/2016 Go to the issue